Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies.
Davis
Stacy A
SA
Johnson
Robert R
RR
Pendleton
John W
JW
D000328:Adult; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D025242:Spondylarthropathies / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D016899:Interferon-beta; D000068800:Etanercept